Roderique JD, Josef CS, Newcomb AH, Reynolds PS, Somera LG, Spiess BD
On the other hand, capsules and nasal sprays will have to travel to your GIT for absorption
(2016) were the first to demonstrate that transplanting fecal matter from PD patients into mice genetically engineered to overexpress alpha-synuclein significantly worsened their motor symptoms compared to mice receiving transplants from healthy human donors
21 CondeJ
Disclosures: Stephen Congly: Axcella Health, Inc.: Grant/Research Support, AstraZenica: Grant/Research Support, Merck: Grant/Research Support, Ipsen: Grant/Research Support, Bausch Health: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, Gilead Sciences Canada: Grant/Research Support, AstraZeneca: Consultant, GSK: Consultant, Mayur Brahmania: Nothing to Disclose, Conar O'Neil: Gilead Sciences: Speaking and Teaching, Gilead Sciences: Advisor, AbbVie: Speaking and Teaching, ViiV: Advisor, ViiV: Speaking and Teaching, Karen Doucette: Roche: Grant/Research Support, GSK: Grant/Research Support, Altimmune: Grant/Research Support, Mang Ma: Nothing to Disclose, Carla Coffin: Gilead Sciences: Grant/Research Support, Janssen Pharmaceuticals: Grant/Research Support, GSK: Speaking and Teaching, Altimmune Pharmacueticals: Fund paid to the University of Calgary, Riche Pharmaceuticals: Grant/Research Support, GSK: Funds paid to the University of Calgary 1709 VARIATION IN NULEOS(T)IDE ANALOGUE USE IN MEDICARE PART D THROUGHOUT THE UNITED STATES Stephen Congly 1 Conar O'Neil 2 Karen Doucette 2 Mang Ma 2 Mayur Brahmania 1 Carla Coffin 1 , 1 University of Calgary, 2 University of Alberta Background: Treatment for chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) suppresses viral replication and prevents progression to fibrosis and liver cancer
10.1016/j.nutres.2013.08.009 297
